Published • loading... • Updated
J&J’s Shockwave Peripheral IVL Evaluated at 24 Months in DISRUPT BTK II Postmarket Study
Summary by Endovascular Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
J&J’s Shockwave Peripheral IVL Evaluated at 24 Months in DISRUPT BTK II Postmarket Study
October 8, 2026—Johnson & Johnson MedTech announced 24-month results from the DISRUPT PAD BTK II postmarket study assessing the continued safety and effectiveness of the company’s Shockwave peripheral intravascular lithotripsy (IVL) system for treating calcified below-the-knee (BTK) lesions in patients with peripheral artery disease (PAD). The company noted that the DISRUPT PAD BTK II study included highly challenging patients including a high p…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
